Navigation Links
Study Validates Clinical Accuracy of 50% Dose Reduction for Positron Emission Mammography
Date:6/7/2011

SAN ANTONIO, June 7, 2011 /PRNewswire/ -- Presented today at the Society of Nuclear Medicine 2011 Annual Meeting researchers from Swedish Medical Center and the University of Washington showed that FDG dose for Positron Emission Mammography (PEM) may be reduced by at least 50% without altering image quality.

PEM is the breast application of the Naviscan high-resolution PET scanner showing the location as well as the metabolic phase of a lesion.  The metabolic view assists physicians in making the optimal cancer care decision by providing an unprecedented ability to distinguish between benign and malignant lesions, what researchers term "specificity."  PEM is different than x-ray mammography in that it is currently not used as a screening modality, rather is deployed to confirm extent of disease and aid in treatment planning in a patient already diagnosed with a primary breast cancer.

"With our limited clinical experience with invasive ductal carcinomas to date the clinical diagnostic quality of images appear equivalent between the 5 millicurie (mCi) dose and the traditional 10 millicurie dose. However the longer uptake time (90-120 minutes) we believe significantly improves lesion to background ratio with our invasive ductal carcinomas," stated Dr. James Rogers, a nuclear medicine physician at Seattle Nuclear Medicine and co-author of the study. "The tradeoff between lowering dose and minimally increasing imaging scan time from a 7 to 10 minute scan appears to be a reasonable imaging strategy. We are still formulating our opinion and strategy in regard to lower FDG doses that are less than 5 millicuries, and are hopeful that an individualized patient strategy based on patient weight will allow us to show that lower FDG doses will be possible for a large number of our patients.  We have not done enough DCIS only patients or Invasive Lobular patients to make a conclusion at this time."

The researchers pre
'/>"/>

SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New Study Finds Patient Adherence to Statin Medications Reduces Hospitalizations and Healthcare Costs
2. Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx® in Directing Chemotherapy in Gynecological Cancers
3. New Study Released Today Showed Patients With Deadly Form of Lung Cancer Lived Longer Without Disease Worsening
4. Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy
5. New Study Questions Ability of Radiology Benefit Managers to Lower Costs
6. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
7. Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization
8. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
9. Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment
10. All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
11. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 Bronstein, Gewirtz & ... purchasers of the securities of PDL BioPharma, Inc. ("PDL ... -News).  Such investors are advised to contact Peretz ... Kimelman at info@bgandg.com or 212-697-6484. ... certain of its executives violated federal securities laws. ...
(Date:9/17/2014)... 2014 , Glenmark,s ... positive data in a Phase 2a proof of concept ... Glenmark Pharmaceuticals today announced that its ... antagonist, GRC 17536 has shown positive data in a ... concept study conducted on 138 patients in ...
(Date:9/17/2014)... 17, 2014   MedeAnalytics today unveils ... brings complete visibility to a provider,s "mid-cycle" to ... reimbursement landscape. Powered by the industry,s leading big ... critical point between patient access and the business ... will improve revenue capture, minimize audit risk and ...
Breaking Medicine Technology:Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
... Oct. 31, 2011 Covance Inc. (NYSE: ... ranked first, by a wide margin, in an independent ... trials. The majority (54 percent) of the study participants ... central laboratory, with investigators citing Covance three times more ...
... InterMune, Inc. (NASDAQ: ITMN ) today ... Shire plc, has been appointed to InterMune,s Board of ... on meeting the needs of the specialist physician. ... a leading global biopharmaceutical company with expertise in the ...
Cached Medicine Technology:Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey 2Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey 3InterMune Appoints Angus C. Russell to Board of Directors 2InterMune Appoints Angus C. Russell to Board of Directors 3
(Date:9/17/2014)... (PRWEB) September 17, 2014 StartX ... revealed 12 companies raising rounds of funding at its ... few hundred investors and media, was the first such ... located next to the university. The presentations were delivered ... adjacent to StartX-QB3 Labs, a 2,000 square foot life ...
(Date:9/17/2014)... Cadiz Laser Spa offers the latest, most ... throughout Central Texas. The newest addition to their ... Using the revolutionary Rejuvapen micro-needling device Cadiz Laser ... a wide variety of skin issues. , The ... Spa is currently offering a special package through ...
(Date:9/17/2014)... (HealthDay News) -- Present-day Europeans are the descendants ... according to a new study. Previous ... and early European farmers. But, a new genetic ... also the descendants of Ancient North Eurasians. Nearly ... third ancestral group, researchers from Harvard Medical School ...
(Date:9/17/2014)... Steven Reinberg HealthDay Reporter ... a key factor to explain why antibiotic-resistant bacteria can thrive ... called plasmids appear to be the culprit. They can easily ... some carry a gene that makes bacteria drug-resistant, a new ... an antibiotic-resistant gene to a class of antibiotic called carbapenems," ...
(Date:9/17/2014)... might be able to reduce the need for invasive ... autoimmune disease lupus. , In a new study, researchers ... from nephritis kidney inflammation to interstitial fibrosis, ... A kidney biopsy is the only existing way to ... extent. , The model could also be used to ...
Breaking Medicine News(10 mins):Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:Revolutionary Collagen Induction Therapy is Now Available at Cadiz Laser Spa 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 2Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 3Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2
... Corporation today announced it has requisitioned a special meeting ... return of capital to NUCRYST shareholders of approximately US$15 ... review alternatives to maximize the value of its 74.5 ... Corporations Act, NUCRYST,s Board of Directors has 20 days ...
... N.J., Dec. 1 ETHICON, Inc., a Johnson & ... of its Professional Wound Care business to One Equity Partners. ... , , Under the terms ... Wound Care product portfolio, which contains such advanced wound care ...
... Dec. 1 Democratic National Committee Chairman Howard Dean today ... 20th Anniversary: , , (Logo: ... "It,s been 20 years since the first World AIDS Day, ... be done to tackle this epidemic with both a national ...
... MassMutual Retirement Services Division has added two new ... has more than tripled in 2008 compared to last ... Dan Darby joined MassMutual on December 1 as nonprofit ... M. Palmer Whitney, national managing director, nonprofit market, for ...
... failure, study says , , MONDAY, Dec. 1 (HealthDay News) ... that cause idiosyncratic drug-induced liver injury (DILI), researchers say. ... cases of acute liver failure in the United States ... acute liver failure. , DILI is caused by a ...
... (PTSD) affects as many as one in five of all ... or terrorism. It has emotionally paralyzed survivors of 9/11 and ... accepted treatment that can lower the chance of developing the ... medical means of preventing PTSD may be just around the ...
Cached Medicine News:Health News:The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 3Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 3Health News:Antibiotics Largest Cause of Drug-Induced Liver Damage 2Health News:Easing the stress of trauma 2
EPS 3501 : 3500 V, 150 mA, 100 W maximum. Constant voltage, constant current, or constant power modes. Stores and recalls three protocols. Excellent for manual DNA sequencing and IEF applications....
... power supply, with temperature probe, 100-120 and 220-240 ... 500 mA, and 400 W. The temperature probe ... and 90 degrees C during electrophoresis. Built-in infrared ... and instructions are provided. Dimensions are 27.5 x ...
... SPECIFICATIONS Form: Granular, free flowing powder EEO(-m r ): ... (3%): less than or equal to 31C Remelt ... Gel Strength (3%): greater than or equal to 500 ... equal to 1000 gm/cm 2 Moisture: less than ...
... chloride (Cl) ≤ 500 mg/kg sulfate (SO 4 ) ... Cd ≤ 5 mg/kg Co ≤ 5 mg/kg Cr ... 10 mg/kg K ≤ 50 mg/kg Mg ≤ 50 ... Ni ≤ 5 mg/kg Pb ≤ 5 mg/kg Zn ...
Medicine Products: